Go online to PeerView.com/KKH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discusses a team-based approach to the management of light chain (AL) amyl
Featuring articles on dupilumab for COPD with type 2 inflammation, a maternal group B streptococcus vaccine, an RNA interference therapeutic agent for hypertension, and the antibody NI006 for depletion of cardiac amyloid; a review article on ob
Vince Nicholas and Paul Pozzo are patient advocacy leaders at the UK ATTR amyloidosis Patient Association. Each live with a variant of the rare disease amyloidosis; ATTR (transthyretin) amyloidosis and wild-type amyloidosis, respectively. In th
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in...The post Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP a